The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to shunt type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma.
The human eye is a specialized sensory organ capable of light reception and able to receive visual images. The trabecular meshwork serves as a drainage channel and is located in anterior chamber angle formed between the iris and the cornea. The trabecular meshwork maintains a balanced pressure in the anterior chamber of the eye by draining aqueous humor from the anterior chamber.
About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentations, etiologies, and treatment modalities. Glaucoma causes pathological changes in the optic nerve, visible on the optic disk, and it causes corresponding visual field loss, resulting in blindness if untreated. Lowering intraocular pressure is the major treatment goal in all glaucomas.
In glaucomas associated with an elevation in eye pressure (intraocular hypertension), the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork allows the aqueous humor (“aqueous”) to enter Schlemm's canal, which then empties into aqueous collector channels in the posterior wall of Schlemm's canal and then into aqueous veins, which form the episcleral venous system. Aqueous humor is a transparent liquid that fills the region between the cornea, at the front of the eye, and the lens. The aqueous humor is continuously secreted by the ciliary body around the lens, so there is a constant flow of aqueous humor from the ciliary body to the eye's front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through the trabecular meshwork (major route) or uveal scleral outflow (minor route). The trabecular meshwork is located between the outer rim of the iris and the back of the cornea, in the anterior chamber angle. The portion of the trabecular meshwork adjacent to Schlemm's canal (the juxtacanilicular meshwork) causes most of the resistance to aqueous outflow.
Glaucoma is grossly classified into two categories: closed-angle glaucoma, also known as angle closure glaucoma, and open-angle glaucoma. Closed-angle glaucoma is caused by closure of the anterior chamber angle by contact between the iris and the inner surface of the trabecular meshwork. Closure of this anatomical angle prevents normal drainage of aqueous humor from the anterior chamber of the eye.
Open-angle glaucoma is any glaucoma in which the angle of the anterior chamber remains open, but the exit of aqueous through the trabecular meshwork is diminished. The exact cause for diminished filtration is unknown for most cases of open-angle glaucoma. Primary open-angle glaucoma is the most common of the glaucomas, and it is often asymptomatic in the early to moderately advanced stage. Patients may suffer substantial, irreversible vision loss prior to diagnosis and treatment. However, there are secondary open-angle glaucomas which may include edema or swelling of the trabecular spaces (e.g., from corticosteroid use), abnormal pigment dispersion, or diseases such as hyperthyroidism that produce vascular congestion.
Current therapies for glaucoma are directed at decreasing intraocular pressure. Medical therapy includes topical ophthalmic drops or oral medications that reduce the production or increase the outflow of aqueous. However, these drug therapies for glaucoma are sometimes associated with significant side effects, such as headache, blurred vision, allergic reactions, death from cardiopulmonary complications, and potential interactions with other drugs. When drug therapy fails, surgical therapy is used. Surgical therapy for open-angle glaucoma consists of laser trabeculoplasty, trabeculectomy, and implantation of aqueous shunts after failure of trabeculectomy or if trabeculectomy is unlikely to succeed. Trabeculectomy is a major surgery that is widely used and is augmented with topically applied anticancer drugs, such as 5-flurouracil or mitomycin-C to decrease scarring and increase the likelihood of surgical success.
Approximately 100,000 trabeculectomies are performed on Medicare-age patients per year in the United States. This number would likely increase if the morbidity associated with trabeculectomy could be decreased. The current morbidity associated with trabeculectomy consists of failure (10-15%); infection (a lifelong risk of 2-5%); choroidal hemorrhage, a severe internal hemorrhage from low intraocular pressure, resulting in visual loss (1%); cataract formation; and hypotony maculopathy (potentially reversible visual loss from low intraocular pressure).
For these reasons, surgeons have tried for decades to develop a workable surgery for the trabecular meshwork.
The surgical techniques that have been tried and practiced are goniotomy/trabeculotomy and other mechanical disruptions of the trabecular meshwork, such as trabeculopuncture, goniophotoablation, laser trabecular ablation, and goniocurretage. These are all major operations and are briefly described below.
Goniotomy/Trabeculotomy: Goniotomy and trabeculotomy are simple and directed techniques of microsurgical dissection with mechanical disruption of the trabecular meshwork. These initially had early favorable responses in the treatment of open-angle glaucoma. However, long-term review of surgical results showed only limited success in adults. In retrospect, these procedures probably failed due to cellular repair and fibrosis mechanisms and a process of “filling in.” Filling in is a detrimental effect of collapsing and closing in of the created opening in the trabecular meshwork. Once the created openings close, the pressure builds back up and the surgery fails.
Trabeculopuncture: Q-switched Neodynium (Nd) YAG lasers also have been investigated as an optically invasive technique for creating full-thickness holes in trabecular meshwork. However, the relatively small hole created by this trabeculopuncture technique exhibits a filling-in effect and fails.
Goniophotoablation/Laser Trabecular Ablation: Goniophotoablation is disclosed by Berlin in U.S. Pat. No. 4,846,172 and involves the use of an excimer laser to treat glaucoma by ablating the trabecular meshwork. This was demonstrated not to succeed by clinical trial. Hill et al. used an Erbium:YAG laser to create full-thickness holes through trabecular meshwork (Hill et al., Lasers in Surgery and Medicine 11:341-346, 1991). This technique was investigated in a primate model and a limited human clinical trial at the University of California, Irvine. Although morbidity was zero in both trials, success rates did not warrant further human trials. Failure was again from filling in of surgically created defects in the trabecular meshwork by repair mechanisms. Neither of these is a viable surgical technique for the treatment of glaucoma.
Goniocurretage: This is an ab interno (from the inside), mechanically disruptive technique that uses an instrument similar to a cyclodialysis spatula with a microcurrette at the tip. Initial results were similar to trabeculotomy: it failed due to repair mechanisms and a process of filling in.
Although trabeculectomy is the most commonly performed filtering surgery, viscocanulostomy (VC) and non penetrating trabeculectomy (NPT) are two new variations of filtering surgery. These are ab externo (from the outside), major ocular procedures in which Schlemm's canal is surgically exposed by making a large and very deep scleral flap. In the VC procedure, Schlemm's canal is cannulated and viscoelastic substance injected (which dilates Schlemm's canal and the aqueous collector channels). In the NPT procedure, the inner wall of Schlemm's canal is stripped off after surgically exposing the canal.
Trabeculectomy, VC, and NPT involve the formation of an opening or hole under the conjunctiva and scleral flap into the anterior chamber, such that aqueous humor is drained onto the surface of the eye or into the tissues located within the lateral wall of the eye. These surgical operations are major procedures with significant ocular morbidity. When trabeculectomy, VC, and NPT are thought to have a low chance for success, a number of implantable drainage devices have been used to ensure that the desired filtration and outflow of aqueous humor through the surgical opening will continue. The risk of placing a glaucoma drainage device also includes hemorrhage, infection, and diplopia (double vision).
Examples of implantable shunts and surgical methods for maintaining an opening for the release of aqueous humor from the anterior chamber of the eye to the sclera or space beneath the conjunctiva have been disclosed in, for example, U.S. Pat. No. 6,059,772 to Hsia et al., and U.S. Pat. No. 6,050,970 to Baerveldt.
All of the above surgeries and variations thereof have numerous disadvantages and moderate success rates. They involve substantial trauma to the eye and require great surgical skill in creating a hole through the full thickness of the sclera into the subconjunctival space. The procedures are generally performed in an operating room and have a prolonged recovery time for vision.
The complications of existing filtration surgery have prompted ophthalmic surgeons to find other approaches to lowering intraocular pressure.
The trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous and, as such, are logical targets for surgical removal in the treatment of open-angle glaucoma. In addition, minimal amounts of tissue are altered and existing physiologic outflow pathways are utilized.
As reported in Arch. Ophthalm. (2000) 118:412, glaucoma remains a leading cause of blindness, and filtration surgery remains an effective, important option in controlling the disease. However, modifying existing filtering surgery techniques in any profound way to increase their effectiveness appears to have reached a dead end. The article further states that the time has come to search for new surgical approaches that may provide better and safer care for patients with glaucoma.
Therefore, there is a great clinical need for a method of treating glaucoma that is faster, safer, and less expensive than currently available modalities.
The trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous and, as such, are logical targets for surgical approach in the treatment of glaucoma. Various embodiments of glaucoma shunts are disclosed herein for aqueous to exit through the trabecular meshwork (major route) or uveal scleral outflow (minor route) or other route effective to reduce intraocular pressure (IOP).
Glaucoma surgical morbidity would greatly decrease if one were to bypass the focal resistance to outflow of aqueous only at the point of resistance, and to utilize remaining, healthy aqueous outflow mechanisms. This is in part because episcleral aqueous humor exerts a backpressure that prevents intraocular pressure from going too low, and one could thereby avoid hypotony. Thus, such a surgery would virtually eliminate the risk of hypotony-related maculopathy and choroidal hemorrhage. Furthermore, visual recovery would be very rapid, and the risk of infection would be very small, reflecting a reduction in incidence from 2-5% to about 0.05%.
U.S. Pat. No. 6,638,239, filed Apr. 14, 2000, entitled APPARATUS AND METHOD FOR TREATING GLAUCOMA, and U.S. Pat. No. 6,736,791, filed Nov. 1, 2000, entitled GLAUCOMA TREATMENT DEVICE, disclose devices and methods of placing a trabecular shunt ab interno, i.e., from inside the anterior chamber through the trabecular meshwork, into Schlemm's canal. The entire contents of each one of these copending patent applications are hereby incorporated by reference herein. The invention encompasses both ab interno and ab externo glaucoma shunts or stents and methods thereof.
Techniques performed in accordance with aspects herein may be referred to generally as “trabecular bypass surgery.” Advantages of this type of surgery include lowering intraocular pressure in a manner which is simple, effective, disease site-specific, and can potentially be performed on an outpatient basis.
Generally, trabecular bypass surgery (TBS) creates an opening, a slit, or a hole through trabecular meshwork with minor microsurgery. TBS has the advantage of a much lower risk of choroidal hemorrhage and infection than prior techniques, and it uses existing physiologic outflow mechanisms. In some aspects, this surgery can potentially be performed under topical or local anesthesia on an outpatient basis with rapid visual recovery. To prevent “filling in” of the hole, a biocompatible elongated device is placed within the hole and serves as a stent. U.S. Pat. No. 6,638,239, filed Apr. 14, 2000, the entire contents of which are hereby incorporated by reference herein, discloses trabecular bypass surgery.
As described in U.S. Pat. No. 6,638,239, filed Apr. 14, 2000, and U.S. Pat. No. 6,736,791, filed Nov. 1, 2000, the entire contents each one of which are hereby incorporated by reference herein, a trabecular shunt or stent for transporting aqueous humor is provided. The trabecular stent includes a hollow, elongate tubular element, having an inlet section and an outlet section. The outlet section may optionally include two segments or elements, adapted to be positioned and stabilized inside Schlemm's canal. In one embodiment, the device appears as a “T” shaped device.
In one aspect of the invention, a delivery apparatus (or “applicator”) is used for placing a trabecular stent through a trabecular meshwork of an eye. Certain embodiments of such a delivery apparatus are disclosed in U.S. application Ser. No. 10/101,548, filed Mar. 18, 2002, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, and U.S. Provisional Application No. 60/276,609, filed Mar. 16, 2001, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, the entire contents of each one of which are hereby incorporated by reference herein.
The stent has an inlet section and an outlet section. The delivery apparatus includes a handpiece, an elongate tip, a holder and an actuator. The handpiece has a distal end and a proximal end. The elongate tip is connected to the distal end of the handpiece. The elongate tip has a distal portion and is configured to be placed through a corneal incision and into an anterior chamber of the eye. The holder is attached to the distal portion of the elongate tip. The holder is configured to hold and release the inlet section of the trabecular stent. The actuator is on the handpiece and actuates the holder to release the inlet section of the trabecular stent from the holder. When the trabecular stent is deployed from the delivery apparatus into the eye, the outlet section is positioned in substantially opposite directions inside Schlemm's canal. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger.
Some aspects of the invention relate to devices for reducing intraocular pressure by providing outflow of aqueous from an anterior chamber of an eye. The device generally comprises an elongated tubular member and cutting means. The tubular member is adapted for extending through a trabecular meshwork of the eye. The tubular member generally comprises a lumen having an inlet port and an outlet port for providing a flow pathway. The cutting means is mechanically connected to the tubular member for creating an incision in the trabecular meshwork for receiving at least a portion of the tubular member.
In one aspect, a self-trephining glaucoma stent is provided for reducing and/or balancing intraocular pressure in an eye. The stent generally comprises a snorkel and a curved blade. The snorkel generally comprises an upper seat for stabilizing said stent within the eye, a shank and a lumen. The shank is mechanically connected to the seat and is adapted for extending through a trabecular meshwork of the eye. The lumen extends through the snorkel and has at least one inlet flow port and at least one outlet flow port. The blade is mechanically connected to the snorkel. The blade generally comprises a cutting tip proximate a distal-most point of the blade for making an incision in the trabecular meshwork for receiving the shank.
Some aspects of the invention relate to methods of implanting a trabecular stent device in an eye. In one aspect, the device has a snorkel mechanically connected to a blade. The blade is advanced blade through a trabecular meshwork of the eye to cut the trabecular meshwork and form an incision therein. At least a portion of the snorkel is inserted in the incision to implant the device in the eye.
Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure. In any of the embodiments, fiducial markings, indicia, or the like and/or positioning of the stent device in a preloaded applicator may be used for proper orientation and alignment of the device during implantation.
Among the advantages of trabecular bypass surgery is its simplicity. The microsurgery may potentially be performed on an outpatient basis with rapid visual recovery and greatly decreased morbidity. There is a lower risk of infection and choroidal hemorrhage, and there is a faster recovery, than with previous techniques.
For purposes of summarizing the invention, certain aspects, advantages and novel features of the invention have been described herein above. Of course, it is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment of the invention. Thus, the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught or suggested herein without necessarily achieving other advantages as may be taught or suggested herein.
All of these embodiments are intended to be within the scope of the invention herein disclosed. These and other embodiments of the invention will become readily apparent to those skilled in the art from the following detailed description of the preferred embodiments having reference to the attached figures, the invention not being limited to any particular preferred embodiment(s) disclosed.
Having thus summarized the general nature of the invention and some of its features and advantages, certain preferred embodiments and modifications thereof will become apparent to those skilled in the art from the detailed description herein having reference to the figures that follow, of which:
The preferred embodiments of the invention described herein relate particularly to surgical and therapeutic treatment of glaucoma through reduction of intraocular pressure. While the description sets forth various embodiment specific details, it will be appreciated that the description is illustrative only and should not be construed in any way as limiting the invention. Furthermore, various applications of the invention, and modifications thereto, which may occur to those who are skilled in the art, are also encompassed by the general concepts described herein.
Referring to
Still referring to
As best illustrated by the drawing of
As shown in
Self-Trephining Glaucoma Stent
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
Referring in particular to
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In modified embodiments, suitable cutting edges may be provided on selected portions of one or more selected blade edges 68, 70, 72, 74 with efficacy, as needed or desired, giving due consideration to the goals of providing suitable cutting means on the stent 30 for effectively cutting through the trabecular meshwork 21 (
Referring in particular to
Still referring in particular to
As shown in the top view of
Referring to in particular to
The stent 30 of the embodiments disclosed herein can be dimensioned in a wide variety of manners. Referring in particular to
Of course, as the skilled artisan will appreciate, that with the stent 30 implanted, the blade 34 may rest at any suitable position within Schlemm's canal 22. For example, the blade 34 may be adjacent to a front wall 90 of Schlemm's canal 22 (as shown in
The trabecular stenting device 30 (
The trabecular stenting device 30 preferably comprises a biocompatible material such that inflammation arising due to irritation between the outer surface of the device 30 and the surrounding tissue is minimized. Biocompatible materials which may be used for the device 30 preferably include, but are not limited to, titanium, titanium alloys, medical grade silicone, e.g., Silastic™, available from Dow Coming Corporation of Midland, Mich.; and polyurethane, e.g., Pellethane™, also available from Dow Corning Corporation.
In other embodiments, the stent device 30 may comprise other types of biocompatible material, such as, by way of example, polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polysilicon, and/or a mixture of the aforementioned biocompatible materials, and the like. In still other embodiments, composite biocompatible material may be used, wherein a surface material may be used in addition to one or more of the aforementioned materials. For example, such a surface material may include polytetrafluoroethylene (PTFE) (such as Teflon™), polyimide, hydrogel, heparin, therapeutic drugs (such as beta-adrenergic antagonists and other anti-glaucoma drugs, or antibiotics), and the like.
In an exemplary embodiment of the trabecular meshwork surgery, the patient is placed in the supine position, prepped, draped and anesthetized as necessary. In one embodiment, a small (less than about 1 mm) incision, which may be self-sealing is made through the cornea 12. The corneal incision can be made in a number of ways, for example, by using a micro-knife, among other tools.
An applicator or delivery apparatus is used to advance the glaucoma stent 30 through the corneal incision and to the trabecular meshwork 21. Some embodiments of such a delivery apparatus are disclosed in U.S. application Ser. No. 10/101,548, filed Mar. 18, 2002, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, and U.S. Provisional Application No. 60/276,609, filed Mar. 16, 2001, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, the entire contents of each one of which are hereby incorporated by reference herein. Some embodiments of a delivery apparatus are also discussed in further detail later herein. Gonioscopic, microscopic, or endoscopic guidance may be used during the trabecular meshwork surgery.
With the device 30 held by the delivery apparatus, the blade 34 of the self-trephining glaucoma stent device 30 is used to cut and/or displace the material of the trabecular meshwork 21. The snorkel shank 40 may also facilitate in removal of this material during implantation. The delivery apparatus is withdrawn once the device 30 has been implanted in the eye 10. As shown in
Advantageously, the embodiments of the self-trephining stent device of the invention allow for a “one-step” procedure to make an incision in the trabecular meshwork and to subsequently implant the stent in the proper orientation and alignment within the eye to allow outflow of aqueous from the anterior chamber through the stent and into Schlemm's canal to lower and/or balance the intraocular pressure (IOP). Desirably, this provides for a faster, safer, and less expensive surgical procedure.
Many complications can arise in trabecular meshwork surgeries, wherein a knife is first used to create an incision in the trabecular meshwork, followed by removal of the knife and subsequent installation of the stent. For instance, the knife may cause some bleeding which clouds up the surgical site. This may require more effort and time to clean the surgical site prior to placement of the stent. Moreover, this may cause the intraocular pressure (IOP) to rise. Thus, undesirably, such a multiple step procedure may demand crisis management which slows down the surgery, makes it less safe, and more expensive.
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the illustrated embodiment of
In the embodiment of
In the illustrated embodiment of
Referring to
In general, any of the blade configurations disclosed herein may be used in conjunction with any of the snorkel configurations disclosed herein or incorporated by reference herein to provide a self-trephining glaucoma stent device for making an incision in the trabecular meshwork for receiving the corresponding snorkel to provide a pathway for aqueous outflow from the eye anterior chamber to Schlemm's canal, thereby effectively lowering and/or balancing the intraocular pressure (IOP). The self-trephining ability of the device, advantageously, allows for a “one-step” procedure in which the incision and placement of the snorkel are accomplished by a single device and operation. In any of the embodiments, fiducial markings or indicia, and/or preselected configuration of the snorkel seat, and/or positioning of the stent device in a preloaded applicator may be used for proper orientation and alignment of the device during implantation.
Delivery Apparatus
In many cases, a surgeon works from a temporal incision when performing cataract or goniometry surgery.
Still referring in particular to
In one aspect of the invention, a delivery apparatus (or “applicator”) is used for placing a trabecular stent through a trabecular meshwork of an eye. Certain embodiments of such a delivery apparatus are disclosed in U.S. application Ser. No. 10/101,548, filed Mar. 18, 2002, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, and U.S. Provisional Application No. 60/276,609, filed Mar. 16, 2001, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, the entire contents of each one of which are hereby incorporated by reference herein.
The stent has an inlet section and an outlet section. The delivery apparatus includes a handpiece, an elongate tip, a holder and an actuator. The handpiece has a distal end and a proximal end. The elongate tip is connected to the distal end of the handpiece. The elongate tip has a distal portion and is configured to be placed through a corneal incision and into an anterior chamber of the eye. The holder is attached to the distal portion of the elongate tip. The holder is configured to hold and release the inlet section of the trabecular stent. The actuator is on the handpiece and actuates the holder to release the inlet section of the trabecular stent from the holder. When the trabecular stent is deployed from the delivery apparatus into the eye, the outlet section is positioned in substantially opposite directions inside Schlemm's canal. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger.
In some embodiments, the holder comprises a clamp. In some embodiments, the apparatus further comprises a spring within the handpiece that is configured to be loaded when the stent is being held by the holder, the spring being at least partially unloaded upon actuating the actuator, allowing for release of the stent from the holder.
In various embodiments, the clamp comprises a plurality of claws configured to exert a clamping force onto the inlet section of the stent. The holder may also comprise a plurality of flanges.
In some embodiments, the distal portion of the elongate tip is made of a flexible material. This can be a flexible wire. The distal portion can have a deflection range, preferably of about 45 degrees from the long axis of the handpiece.
The delivery apparatus can further comprise an irrigation port in the elongate tip.
Some aspects include a method of placing a trabecular stent through a trabecular meshwork of an eye, the stent having an inlet section and an outlet section, including advancing a delivery apparatus holding the trabecular stent through an anterior chamber of the eye and into the trabecular meshwork, placing part of the stent through the trabecular meshwork and into a Schlemm's canal of the eye; and releasing the stent from the delivery apparatus.
In various embodiments, the method includes using a delivery apparatus that comprises a handpiece having a distal end and a proximal end; an elongate tip connected to the distal end of the handpiece, the elongate tip having a distal portion and being configured to be placed through a corneal incision and into an anterior chamber of the eye; a holder attached to the distal portion of the elongate tip, the holder configured to hold and release the inlet section of the trabecular stent; and an actuator on the handpiece that actuates the holder to release the inlet section of the trabecular stent from the holder.
In one aspect, the trabecular stent is removably attached to a delivery apparatus (also known as “applicator”). When the trabecular stent is deployed from the delivery apparatus into the eye, the outlet section is positioned in substantially opposite directions inside Schlemm's canal. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger. In some embodiments, the delivery applicator may be a guidewire, an expandable basket, an inflatable balloon, or the like.
Other Embodiments
Screw/Barb Anchored Stent:
In use, the stent 30f (
Referring to
Still referring to
Deeply Threaded Stent:
In use, the stent 30g (
Referring to
One suitable applicator or delivery apparatus for this stent 30g (
Referring to
Rivet Style Stent:
Referring to
The lumen 42h (
Referring to
Grommet Style Stent:
In use, the stent 30i (
Referring to
Still referring to
In operation, the glaucoma stent device 30i′ of
Generally, the tapered base 146′ is attached to the waist portion or shank 40i′ which is attached to the head or seat 38i′ to form the glaucoma stent device 30i′ illustrated in
In some embodiments, there are four side-ports 56i′ intersecting the lumen 42i′ in the region of the tapered base 146′. In some embodiments, the at least one side-port 56i′ intersects perpendicular to the lumen 42i′ (as shown in
In some embodiments, the head or seat 38i′of the glaucoma stent device 30i′ has a diameter in the range of about 100-3000 μm, about 150-3750 μm, about 200-3500 μm, about 200-3250 μm, about 250-3000 μm, about 300-2750 μm, about 350-2500 μm, about 375-2250 μm, about 400-2000 μm, about 450-1750 μm, about 500-1500 μm, about 550-1250 μm, about 600-1000 μm, and about 650-800 μm or any other diameter which fits within the eye and serves to anchor the glaucoma stent device 30i′ appropriately.
In some embodiments, the head or seat depth 38d of the glaucoma stent device 30i′ is in the range of about 50-1000 μm, about 60-900 μm, about 70-800 μm, about 80-700 μm, about 90-600 μm, about 100-500 μm, about 110-400 μm, and about 120-300 including about 130-200 μm or any other depth which allows the glaucoma stent device 30i′ to seat in the eye and maintain structural integrity and/or alignment of side-ports 56i′ to Schlemm's canal.
In some embodiments, the waist portion or shank depth 40m of the glaucoma stent device 30i′ is approximately equal to the thickness of the trabecular meshwork 21 of
In some embodiments, the waist portion or shank external diameter 40n of the glaucoma stent device 30i′ is in the range of about 100-1500 μm, about 150-1400 μm, about 160-1300 μm, about 170-1200 μm, about 180-1100 μm, about 190-1000 μm, about 200-900 μm, about 210-800 μm, about 220-700 μm, about 230-600 μm, about 240-500 μm, about 250-400, and about 260-300 μm.
In some embodiments, angle α formed by the attachment of the head or seat 38i′ to the waist portion or shank 40i′ is in the range of about 5-45°, about 7.5-40°, about 10-35°, about 12.5-30°, about 15-25°, and about 17.5-20°. Generally, the lower the angle α, the more of the head or seat 38i′portion of the glaucoma stent device 30i′ can be in contact with the trabecular meshwork 21 of
In some embodiments, the angle θ of the tapered base 146′ is in the range of about 45-80°, about 47.5-77.5°, about 50-75°, about 52.5-72.5°, about 55-70°, about 57.5-67.5°, and about 60-65° or any other angle appropriate for fitting inside Schlemm's canal and helping in anchoring the glaucoma stent device 30i′ in the eye.
In some embodiments, the tapered base 146′ is approximately as deep as is Schlemm's canal. In some embodiments, the periphery of the tapered base 146′ is approximately equal to the periphery of the cross section of Schlemm's canal. In some embodiments, the tapered base 146′ is flattened (as shown in
In some embodiments, the head or seat side-port 57i′ can extend through the head or seat 38i′ (e.g., parallel to the planar surface of the head or seat 38i′). In some embodiments, the head or seat side-port 57i′ can be disposed parallel to the at least one side-port 56i′ in the tapered base 146′.
In some embodiments, there are four head or seat side-ports 57i′ intersecting the lumen 42i′ in the region of the head or seat 38i′. In some embodiments, the at least one head or seat side-port 57i′ intersects perpendicular to the lumen 42i′ (as shown in
The glaucoma stent device 30i′ illustrated in
In some embodiments, the head or seat half-cylinder side-port 57j′ can extend through the head or seat 38i′ (e.g., parallel to the planar surface of the head or seat 38i′). In some embodiments, the head or seat half-cylinder side-port 57j′ can be disposed parallel to the at least one side-port 56i′ in the tapered base 146′.
In some embodiments, there are four head or seat half-cylinder side-ports 57j′ intersecting the lumen 42i′ in the region of the head or seat 38i′. In some embodiments, the at least one head or seat half-cylinder side-port 57j′ intersects perpendicular to the lumen 42i′ (as shown in
In some embodiments, the head or seat shank 40k′ can extend from the back of the head or seat 38i′. In some embodiments, the head or seat shank 40k′ can have a diameter less than the diameter of the head or seat 38i′. In some embodiments, the diameter of the head or seat shank 40k′ can be in the range of about 20-100% of the diameter of the head or seat 38i′, about 30-90% of the diameter of the head or seat 38i′, about 40-80% of the diameter of the head or seat 38i′ about 50-70% of the diameter of the head or seat 38i′, and about 60% of the diameter of the head or seat 38i′.
In some embodiments, the head or seat shank 40k′ has a thickness in the range of about 100-500 μm, about 110-450 μm, about 120-400 μm, about 130-350 μm, about 140-300 μm, about 150-250 μm, and about 160-200 μm.
In some embodiments, the head or seat button 38k′ can extend from the back of the head or seat shank 40k′. In some embodiments, the head or seat button 38k′ can have a head or seat button dome 38n. In other embodiments, the head or seat button 38k′ is flat. In some embodiments, the head or seat button 38k′ can have a diameter the same as the diameter of the head or seat 38i′. In some embodiments, the head or seat button 38k′ can have a diameter that is greater than the diameter of the head or seat 38i′. In some embodiments, the head or seat button 38k′ can have a diameter that is less than the diameter of the head or seat 38i′. In some embodiments, the diameter of the head or seat button 38k′ can be in the range of about 50-150% of the diameter of the head or seat 38i′, about 60-140% of the diameter of the head or seat 38i′, about 70-130% of the diameter of the head or seat 38i′, about 80-120% of the diameter of the head or seat 38i′, about 90-110% of the diameter of the head or seat 38i′, and about 100% of the diameter of the head or seat 38i′.
In some embodiments, the head or seat button 38k′ has a thickness in the range of about 100-500 μm, about 110-450 μm, about 120-400 μm, about 130-350 μm, about 140-300 μm, about 150-250 μm, and about 160-200 μm.
In some embodiments, the head or seat shank side-port 57k′ can extend through the head or seat shank 40k′ (e.g., parallel to the planar surface of the head or seat 38i′). In some embodiments, the head or seat shank side-port 57k′ can be disposed parallel to the at least one side-port 56i′ in the tapered base 146′.
In some embodiments, there are four head or seat shank side-ports 57k′ intersecting the lumen 42i′ in the region of the head or seat shank 40k′. In some embodiments, the at least one head or seat shank side-port 57k′ intersects perpendicular to the lumen 42i′ (as shown in
In some embodiments, one or more of the glaucoma stent devices discussed above may be delivered into the eye with a delivery device such as disclosed in the attached Appendix A which is a part of the present specification. One or more glaucoma stents may be preloaded onto the delivery device to form a glaucoma stent/delivery device system.
Biointeractive Stent:
In one embodiment, the biointeractive layer 148 (
Referring to
Still referring to
Glued or Welded Stent:
The stent 30k is advanced through the trabecular meshwork 21 until the head or seat 38k comes to rest on the trabecular meshwork 21, that is, the head lower surface 46k abuts against the trabecular meshwork 21, and the glue or weld 152 is applied or formed therebetween, as shown in
Referring to
Still referring to
Hydrophilic Latching Stent:
Referring to
Still referring to
Photodynamic Stent:
It is commonly known that there is a diurnal variation in the aqueous humor production by the eye—it is higher during the day than it is at night. The lumen 42n of the stent 30n responds to light entering the cornea during the day by expanding and allowing higher flow of aqueous through the lumen 42n and into Schlemm's canal 22. This expansion is generally indicated by the smaller arrows 156 (
This photodynamic implementation is shown in
Referring to
Still referring to
Collector Channel Alignment Stent:
In the illustrated embodiment of
Referring to
Barbed Stent (Anterior Chamber to Collector Channel):
In the illustrated embodiment of
Referring to
Valved Tube Stent (Anterior Chamber to Choroid):
Osmotic Membrane (Anterior Chamber to Choroid):
Clinically, the choroid 17 (
Ab Externo Insertion of Stent via Small Puncture:
Referring to
This ultra-microscopic device 30u (
Targeted Drug Delivery to the Trabecular Meshwork:
A drug that is designed to target the trabecular meshwork 21 to increase its porosity, or improve the active transport across the endothelial layer of Schlemm's canal 22 can be stored in this small implant 30v (
While the components and techniques of the invention have been described with a certain degree of particularity, it is manifest that many changes may be made in the specific designs, constructions and methodology herein above described without departing from the spirit and scope of this disclosure. It should be understood that the invention is not limited to the embodiments set forth herein for purposes of exemplification, but is to be defined only by a fair reading of the appended claims, including the full range of equivalency to which each element thereof is entitled.
This application is a continuation application of U.S. patent application Ser. No. 14/207,240 filed Mar. 12, 2014, now U.S. Pat. No. 10,517,759, titled GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT, which claims priority benefit of U.S. Provisional Application No. 61/794,832 filed Mar. 15, 2013, titled GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT, the entire contents of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2031754 | Mills | Feb 1936 | A |
2127903 | Bowen | Aug 1938 | A |
3159161 | Ness | Dec 1964 | A |
3416530 | Ness | Dec 1968 | A |
3710795 | Higuchi et al. | Jan 1973 | A |
3717151 | Collett | Feb 1973 | A |
3788327 | Donowitz et al. | Jan 1974 | A |
3827700 | Kaller | Aug 1974 | A |
3863623 | Trueblood et al. | Feb 1975 | A |
3915172 | Krejci et al. | Oct 1975 | A |
3948271 | Akiyama | Apr 1976 | A |
3948871 | Butterfield et al. | Apr 1976 | A |
3961628 | Arnold | Jun 1976 | A |
4030480 | Meyer | Jun 1977 | A |
4037604 | Newkirk | Jul 1977 | A |
4043346 | Mobley et al. | Aug 1977 | A |
4093708 | Zaffaroni et al. | Jun 1978 | A |
4113088 | Binkhorst | Sep 1978 | A |
4168697 | Cantekin | Sep 1979 | A |
4175563 | Arenberg et al. | Nov 1979 | A |
4402681 | Haas et al. | Sep 1983 | A |
4428746 | Mendez | Jan 1984 | A |
4449974 | Messingschlager | May 1984 | A |
4450150 | Sidman | May 1984 | A |
4457757 | Molteno | Jul 1984 | A |
4468216 | Muto | Aug 1984 | A |
4501274 | Skjaerpe | Feb 1985 | A |
4554918 | White | Nov 1985 | A |
4604087 | Joseph | Aug 1986 | A |
4632842 | Karwoski et al. | Dec 1986 | A |
4634418 | Binder | Jan 1987 | A |
4692142 | Dignam et al. | Sep 1987 | A |
4718907 | Karwoski et al. | Jan 1988 | A |
4722724 | Schocket | Feb 1988 | A |
4733665 | Palmaz | Mar 1988 | A |
4743248 | Bartoo et al. | May 1988 | A |
4750901 | Molteno | Jun 1988 | A |
4787885 | Binder | Nov 1988 | A |
4804382 | Turina et al. | Feb 1989 | A |
4820626 | Williams et al. | Apr 1989 | A |
4826478 | Schocket | May 1989 | A |
4828439 | Giannuzi | May 1989 | A |
4846172 | Berlin | Jul 1989 | A |
4853224 | Wong | Aug 1989 | A |
4886488 | White | Dec 1989 | A |
4936825 | Ungerleider | Jun 1990 | A |
4946436 | Smith | Aug 1990 | A |
4955881 | Eckenhoff | Sep 1990 | A |
4968296 | Ritch et al. | Nov 1990 | A |
4986810 | Semrad | Jan 1991 | A |
4997652 | Wong | Mar 1991 | A |
5005577 | Frenekl | Apr 1991 | A |
5017381 | Maruyama et al. | May 1991 | A |
5041081 | Odrich | Aug 1991 | A |
5073163 | Lippman | Dec 1991 | A |
5092837 | Ritch et al. | Mar 1992 | A |
5116327 | Seder et al. | May 1992 | A |
5127901 | Odrich | Jul 1992 | A |
5128145 | Edgren et al. | Jul 1992 | A |
5139502 | Berg et al. | Aug 1992 | A |
5164188 | Wong | Nov 1992 | A |
5171213 | Price, Jr. | Dec 1992 | A |
5178604 | Baerveldt et al. | Jan 1993 | A |
5180362 | Worst | Jan 1993 | A |
5207685 | Cinberg et al. | May 1993 | A |
5246451 | Trescony et al. | Sep 1993 | A |
5248231 | Denham et al. | Sep 1993 | A |
5300020 | L'Esperance, Jr. | Apr 1994 | A |
5318513 | Leib et al. | Jun 1994 | A |
5326345 | Price, Jr. | Jul 1994 | A |
5334137 | Freeman | Aug 1994 | A |
5338291 | Speckman et al. | Aug 1994 | A |
5342370 | Simon et al. | Aug 1994 | A |
5346464 | Camras | Sep 1994 | A |
5358492 | Feibus | Oct 1994 | A |
5360399 | Stegmann | Nov 1994 | A |
5370607 | Memmen | Dec 1994 | A |
5370641 | O'Donnell, Jr. | Dec 1994 | A |
5372577 | Ungerleider | Dec 1994 | A |
5378474 | Morella et al. | Jan 1995 | A |
5378475 | Smith et al. | Jan 1995 | A |
5380290 | Makower et al. | Jan 1995 | A |
5397300 | Baerveldt et al. | Mar 1995 | A |
5433701 | Rubinstein | Jul 1995 | A |
5443505 | Wong et al. | Aug 1995 | A |
5454796 | Krupin | Oct 1995 | A |
5476445 | Baerveldt et al. | Dec 1995 | A |
5486165 | Stegmann | Jan 1996 | A |
5520631 | Nordquist et al. | May 1996 | A |
5558629 | Baerveldt et al. | Sep 1996 | A |
5558630 | Fisher | Sep 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
RE35390 | Smith | Dec 1996 | E |
5626558 | Suson | May 1997 | A |
5626559 | Solomon | May 1997 | A |
5629008 | Lee | May 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5643321 | McDevitt | Jul 1997 | A |
5651782 | Simon et al. | Jul 1997 | A |
5676679 | Simon et al. | Oct 1997 | A |
5681275 | Ahmed | Oct 1997 | A |
5702414 | Richter et al. | Dec 1997 | A |
5702419 | Berry et al. | Dec 1997 | A |
5704907 | Nordquist et al. | Jan 1998 | A |
5713844 | Peyman | Feb 1998 | A |
5722948 | Gross | Mar 1998 | A |
5723005 | Herrick | Mar 1998 | A |
5725529 | Nicholson et al. | Mar 1998 | A |
5741333 | Frid | Apr 1998 | A |
5743868 | Brown et al. | Apr 1998 | A |
5752928 | de Roulhac et al. | May 1998 | A |
5762625 | Igaki | Jun 1998 | A |
5766242 | Wong et al. | Jun 1998 | A |
5766243 | Christensen et al. | Jun 1998 | A |
5773019 | Ashton et al. | Jun 1998 | A |
5785674 | Mateen | Jul 1998 | A |
5800376 | Vaskelis | Sep 1998 | A |
5807302 | Wandel | Sep 1998 | A |
5810870 | Myers et al. | Sep 1998 | A |
5824071 | Nelson et al. | Oct 1998 | A |
5824072 | Wong | Oct 1998 | A |
5830171 | Wallace | Nov 1998 | A |
5865831 | Cozean et al. | Feb 1999 | A |
5868697 | Richter et al. | Feb 1999 | A |
5869079 | Wong et al. | Feb 1999 | A |
5879319 | Pynson et al. | Mar 1999 | A |
5882327 | Jacob | Mar 1999 | A |
5902598 | Chen et al. | May 1999 | A |
5908449 | Bruchman et al. | Jun 1999 | A |
5913852 | Magram | Jun 1999 | A |
5932299 | Katoot | Aug 1999 | A |
5980548 | Evans | Nov 1999 | A |
6007510 | Nigam | Dec 1999 | A |
6007511 | Prywes | Dec 1999 | A |
6033434 | Borghi | Mar 2000 | A |
6050970 | Baeverldt | Apr 2000 | A |
6077299 | Adelberg et al. | Jun 2000 | A |
6102045 | Nordquist et al. | Aug 2000 | A |
6142990 | Burk | Nov 2000 | A |
6146387 | Trott et al. | Nov 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6168575 | Soltanpour | Jan 2001 | B1 |
6174305 | Mikus et al. | Jan 2001 | B1 |
6186974 | Allan et al. | Feb 2001 | B1 |
6196993 | Cohan et al. | Mar 2001 | B1 |
6203513 | Yaron et al. | Mar 2001 | B1 |
6231597 | Deem et al. | May 2001 | B1 |
6241721 | Cozean et al. | Jun 2001 | B1 |
6261256 | Ahmed | Jul 2001 | B1 |
6290684 | Herrick | Sep 2001 | B1 |
6306114 | Freeman et al. | Oct 2001 | B1 |
6328758 | Tornier et al. | Dec 2001 | B1 |
6331313 | Wong et al. | Dec 2001 | B1 |
6358222 | Grundei | Mar 2002 | B1 |
6363938 | Saadat et al. | Apr 2002 | B2 |
6375642 | Grieshaber et al. | Apr 2002 | B1 |
6375972 | Guo et al. | Apr 2002 | B1 |
6423001 | Abreu | Jul 2002 | B1 |
6443893 | Schnakenberg et al. | Sep 2002 | B1 |
6450984 | Lynch et al. | Sep 2002 | B1 |
6464724 | Lynch et al. | Oct 2002 | B1 |
6468283 | Richter et al. | Oct 2002 | B1 |
6494857 | Neuhann | Dec 2002 | B1 |
6508779 | Suson | Jan 2003 | B1 |
6517483 | Park et al. | Feb 2003 | B2 |
6524275 | Lynch et al. | Feb 2003 | B1 |
6533768 | Hill | Mar 2003 | B1 |
6544249 | Yu et al. | Apr 2003 | B1 |
6582453 | Tran et al. | Jun 2003 | B1 |
6585753 | Eder et al. | Jul 2003 | B2 |
6589198 | Soltanpour et al. | Jul 2003 | B1 |
6589203 | Mitrev | Jul 2003 | B1 |
6595945 | Brown | Jul 2003 | B2 |
6605053 | Kamm et al. | Aug 2003 | B1 |
6623283 | Torigian et al. | Sep 2003 | B1 |
6626858 | Lynch et al. | Sep 2003 | B2 |
6638239 | Bergheim et al. | Oct 2003 | B1 |
6666213 | Svadovskiy | Dec 2003 | B2 |
6666841 | Gharib et al. | Dec 2003 | B2 |
6682500 | Soltanpour et al. | Jan 2004 | B2 |
6699211 | Savage | Mar 2004 | B2 |
6712764 | Jeffries et al. | Mar 2004 | B2 |
6726666 | de Juan, Jr. | Apr 2004 | B2 |
6726676 | Stegmann et al. | Apr 2004 | B2 |
D490152 | Myall et al. | May 2004 | S |
6730056 | Ghaem et al. | May 2004 | B1 |
6736791 | Tu et al. | May 2004 | B1 |
6764698 | Byun et al. | Jul 2004 | B1 |
6780164 | Bergheim et al. | Aug 2004 | B2 |
6783544 | Lynch et al. | Aug 2004 | B2 |
6827699 | Lynch et al. | Dec 2004 | B2 |
6827700 | Lynch et al. | Dec 2004 | B2 |
6893413 | Martin | May 2005 | B2 |
6939298 | Brown et al. | Sep 2005 | B2 |
6939299 | Petersen et al. | Sep 2005 | B1 |
6955656 | Bergheim et al. | Oct 2005 | B2 |
6962573 | Wilcox | Nov 2005 | B1 |
6966888 | Cullen et al. | Nov 2005 | B2 |
6981958 | Gharib et al. | Jan 2006 | B1 |
6998137 | Shih et al. | Feb 2006 | B2 |
7094225 | Tu et al. | Aug 2006 | B2 |
7101402 | Phelps et al. | Sep 2006 | B2 |
7101567 | Sano et al. | Sep 2006 | B1 |
7135009 | Tu et al. | Nov 2006 | B2 |
7144616 | Unger et al. | Dec 2006 | B1 |
7163543 | Smedley et al. | Jan 2007 | B2 |
7186232 | Smedley et al. | Mar 2007 | B1 |
7192412 | Zhou et al. | Mar 2007 | B1 |
7192484 | Chappa et al. | Mar 2007 | B2 |
7220238 | Lynch et al. | May 2007 | B2 |
7252006 | Tai et al. | Aug 2007 | B2 |
7273475 | Tu et al. | Sep 2007 | B2 |
7294115 | Wilk | Nov 2007 | B1 |
7297130 | Bergheim et al. | Nov 2007 | B2 |
7331984 | Tu et al. | Feb 2008 | B2 |
7364564 | Sniegowski et al. | Apr 2008 | B2 |
7431710 | Tu et al. | Oct 2008 | B2 |
7445793 | Niwa et al. | Nov 2008 | B2 |
7488303 | Haffner et al. | Feb 2009 | B1 |
RE40722 | Chappa | Jun 2009 | E |
7563241 | Tu et al. | Jul 2009 | B2 |
7641627 | Camras et al. | Jan 2010 | B2 |
7678065 | Haffner et al. | Mar 2010 | B2 |
7695135 | Rosenthal | Apr 2010 | B1 |
7708711 | Tu et al. | May 2010 | B2 |
7776024 | Santini et al. | Aug 2010 | B2 |
7811268 | Maldon Ado Bas | Oct 2010 | B2 |
7815592 | Coroneo | Oct 2010 | B2 |
7850637 | Lynch et al. | Dec 2010 | B2 |
7857782 | Tu et al. | Dec 2010 | B2 |
7862531 | Yaron et al. | Jan 2011 | B2 |
7867186 | Haffner et al. | Jan 2011 | B2 |
7867205 | Bergheim et al. | Jan 2011 | B2 |
7879001 | Haffner et al. | Feb 2011 | B2 |
7879079 | Tu et al. | Feb 2011 | B2 |
7951155 | Smedley et al. | May 2011 | B2 |
7997460 | Badawi et al. | Aug 2011 | B2 |
8007459 | Haffner et al. | Aug 2011 | B2 |
D645489 | Gille et al. | Sep 2011 | S |
D645490 | Gille et al. | Sep 2011 | S |
8034016 | Yaron et al. | Oct 2011 | B2 |
8034105 | Stegmann et al. | Oct 2011 | B2 |
8062244 | Tu et al. | Nov 2011 | B2 |
8070290 | Gille et al. | Dec 2011 | B2 |
8075511 | Tu et al. | Dec 2011 | B2 |
8118768 | Tu et al. | Feb 2012 | B2 |
8142364 | Haffner et al. | Mar 2012 | B2 |
8152752 | Lynch et al. | Apr 2012 | B2 |
8267882 | Euteneuer et al. | Sep 2012 | B2 |
8267995 | Castillejos | Sep 2012 | B2 |
8273050 | Bergheim et al. | Sep 2012 | B2 |
8333742 | Bergheim et al. | Dec 2012 | B2 |
8337445 | Tu et al. | Dec 2012 | B2 |
8348877 | Tu et al. | Jan 2013 | B2 |
8388568 | Lynch et al. | Mar 2013 | B2 |
8404269 | Snyder et al. | Mar 2013 | B2 |
8414518 | Schieber et al. | Apr 2013 | B2 |
8419673 | Rickard | Apr 2013 | B2 |
8425449 | Wardle et al. | Apr 2013 | B2 |
8439972 | Badawi et al. | May 2013 | B2 |
8444589 | Silvestrini | May 2013 | B2 |
8454582 | Dejuan et al. | Jun 2013 | B2 |
8475374 | Irazoqui et al. | Jul 2013 | B2 |
8506515 | Burns et al. | Aug 2013 | B2 |
8545431 | Rickard | Oct 2013 | B2 |
8579846 | Tu et al. | Nov 2013 | B2 |
8579848 | Field et al. | Nov 2013 | B2 |
8585631 | Dacquay | Nov 2013 | B2 |
8585664 | Dos Santos et al. | Nov 2013 | B2 |
8603024 | Bohm et al. | Dec 2013 | B2 |
8617094 | Smedley et al. | Dec 2013 | B2 |
8656958 | Unger et al. | Feb 2014 | B2 |
8657776 | Wardle et al. | Feb 2014 | B2 |
8721580 | Rickard et al. | May 2014 | B2 |
8753305 | Field et al. | Jun 2014 | B2 |
8771217 | Lynch et al. | Jul 2014 | B2 |
8771220 | Nissan | Jul 2014 | B2 |
8801648 | Bergheim et al. | Aug 2014 | B2 |
8808219 | Bergheim et al. | Aug 2014 | B2 |
8808222 | Schieber et al. | Aug 2014 | B2 |
8808224 | Rickard | Aug 2014 | B2 |
8814820 | Bergheim et al. | Aug 2014 | B2 |
8840578 | Dos Santos et al. | Sep 2014 | B2 |
8864701 | Dos Santos et al. | Oct 2014 | B2 |
8882781 | Smedley et al. | Nov 2014 | B2 |
8956320 | Ovchinnikov et al. | Feb 2015 | B2 |
8986240 | Dos Santos et al. | Mar 2015 | B2 |
8998838 | Yalamanchili | Apr 2015 | B2 |
9022967 | Oliver et al. | May 2015 | B2 |
9066782 | Tu et al. | Jun 2015 | B2 |
9072588 | Bohm et al. | Jul 2015 | B2 |
9125721 | Field | Sep 2015 | B2 |
9132034 | Dos Santos | Sep 2015 | B2 |
9155653 | Field | Oct 2015 | B2 |
9155654 | Tu et al. | Oct 2015 | B2 |
9173775 | Haffner et al. | Nov 2015 | B2 |
9220632 | Smedley et al. | Dec 2015 | B2 |
9226851 | Gunn | Jan 2016 | B2 |
9283115 | Lind et al. | Mar 2016 | B2 |
9289324 | Johnson et al. | Mar 2016 | B2 |
9301875 | Tu et al. | Apr 2016 | B2 |
9492320 | Lynch et al. | Nov 2016 | B2 |
9554940 | Haffner et al. | Jan 2017 | B2 |
9561131 | Tu et al. | Feb 2017 | B2 |
9572963 | Tu et al. | Feb 2017 | B2 |
9592151 | Rangel-Friedman et al. | Mar 2017 | B2 |
9597230 | Haffner et al. | Mar 2017 | B2 |
9603738 | Haffner et al. | Mar 2017 | B2 |
9603741 | Berlin | Mar 2017 | B2 |
9636255 | Haffner et al. | May 2017 | B2 |
9668915 | Haffner et al. | Jun 2017 | B2 |
9730638 | Haffner et al. | Aug 2017 | B2 |
9789001 | Tu et al. | Oct 2017 | B2 |
9827143 | Lynch | Nov 2017 | B2 |
9833357 | Berlin | Dec 2017 | B2 |
9962290 | Burns et al. | May 2018 | B2 |
9987472 | Tu et al. | Jun 2018 | B2 |
9993368 | Bergheim et al. | Jun 2018 | B2 |
D833008 | Kalina, Jr. et al. | Nov 2018 | S |
10159601 | Berlin | Dec 2018 | B2 |
10183551 | Rangel-Friedman et al. | Jan 2019 | B2 |
10206813 | Haffner et al. | Feb 2019 | B2 |
D846738 | Kalina, Jr. et al. | Apr 2019 | S |
10245178 | Heitzmann et al. | Apr 2019 | B1 |
10271989 | Haffner et al. | Apr 2019 | B2 |
10285853 | Rangel-Friedman et al. | May 2019 | B2 |
10285856 | Tu et al. | May 2019 | B2 |
10406029 | Tu et al. | Sep 2019 | B2 |
10485701 | Haffner et al. | Nov 2019 | B2 |
10485702 | Bergheim et al. | Nov 2019 | B2 |
10492950 | Lynch et al. | Dec 2019 | B2 |
10499809 | Kalina, Jr. et al. | Dec 2019 | B2 |
10517759 | Grimaldi | Dec 2019 | B2 |
10568762 | Lynch et al. | Feb 2020 | B2 |
D886997 | Kalina, Jr. et al. | Jun 2020 | S |
10674906 | Kalina, Jr. et al. | Jun 2020 | B2 |
10813789 | Haffner et al. | Oct 2020 | B2 |
D901683 | Kalina, Jr. et al. | Nov 2020 | S |
10828195 | Burns et al. | Nov 2020 | B2 |
10828473 | Haffner et al. | Nov 2020 | B2 |
10959941 | Haffner | Mar 2021 | B2 |
11019996 | Kalina, Jr. et al. | Jun 2021 | B2 |
11019997 | Kalina, Jr. et al. | Jun 2021 | B2 |
11116625 | Kalina, Jr. | Sep 2021 | B2 |
D938585 | Kalina, Jr. et al. | Dec 2021 | S |
11197780 | Haffner et al. | Dec 2021 | B2 |
11253394 | Haffner et al. | Feb 2022 | B2 |
11426306 | Haffner et al. | Mar 2022 | B2 |
11318043 | Heitzrnann et al. | May 2022 | B2 |
11376040 | Kalina, Jr. et al. | Jul 2022 | B2 |
20010000527 | Yaron et al. | Apr 2001 | A1 |
20010053873 | Schaaf et al. | Dec 2001 | A1 |
20020013546 | Grieshaber et al. | Jan 2002 | A1 |
20020013572 | Berlin | Jan 2002 | A1 |
20020026200 | Savage | Feb 2002 | A1 |
20020052640 | Bigus et al. | May 2002 | A1 |
20020082591 | Haefliger | Jun 2002 | A1 |
20020087111 | Ethier et al. | Jul 2002 | A1 |
20020099434 | Buscemi et al. | Jul 2002 | A1 |
20020102307 | Guo et al. | Aug 2002 | A1 |
20020133168 | Smedley et al. | Sep 2002 | A1 |
20020143284 | Tu et al. | Oct 2002 | A1 |
20020156413 | Williams et al. | Oct 2002 | A1 |
20020169468 | Brown | Nov 2002 | A1 |
20020177856 | Richter et al. | Nov 2002 | A1 |
20020188308 | Tu et al. | Dec 2002 | A1 |
20020193725 | Odrich | Dec 2002 | A1 |
20030019833 | Unger et al. | Jan 2003 | A1 |
20030055372 | Lynch et al. | Mar 2003 | A1 |
20030060752 | Bergheim et al. | Mar 2003 | A1 |
20030079329 | Yaron et al. | May 2003 | A1 |
20030083646 | Sirhan et al. | May 2003 | A1 |
20030088260 | Smedley et al. | May 2003 | A1 |
20030097151 | Smedley et al. | May 2003 | A1 |
20030135149 | Cullen et al. | Jul 2003 | A1 |
20030139729 | Stegmann et al. | Jul 2003 | A1 |
20030153863 | Patel | Aug 2003 | A1 |
20030176854 | Rodstrom | Sep 2003 | A1 |
20030181848 | Bergheim et al. | Sep 2003 | A1 |
20030187384 | Bergheim et al. | Oct 2003 | A1 |
20030208163 | Yaron et al. | Nov 2003 | A1 |
20030212383 | Cote et al. | Nov 2003 | A1 |
20030229303 | Haffner et al. | Dec 2003 | A1 |
20030236483 | Ren | Dec 2003 | A1 |
20030236484 | Lynch et al. | Dec 2003 | A1 |
20040024345 | Gharib et al. | Feb 2004 | A1 |
20040059248 | Messner et al. | Mar 2004 | A1 |
20040076676 | Tojo et al. | Apr 2004 | A1 |
20040076868 | Tojo et al. | Apr 2004 | A1 |
20040088048 | Richter et al. | May 2004 | A1 |
20040092856 | Dahan | May 2004 | A1 |
20040102729 | Haffner et al. | May 2004 | A1 |
20040111050 | Smedley et al. | Jun 2004 | A1 |
20040111080 | Harper et al. | Jun 2004 | A1 |
20040115268 | Ashton et al. | Jun 2004 | A1 |
20040127843 | Tu et al. | Jul 2004 | A1 |
20040147870 | Burns et al. | Jul 2004 | A1 |
20040154946 | Solovay et al. | Aug 2004 | A1 |
20040162545 | Brown et al. | Aug 2004 | A1 |
20040176341 | Chou et al. | Sep 2004 | A1 |
20040180075 | Robinson et al. | Sep 2004 | A1 |
20040193095 | Shadduck | Sep 2004 | A1 |
20040193262 | Shadduck | Sep 2004 | A1 |
20040210181 | Vass et al. | Oct 2004 | A1 |
20040210185 | Tu et al. | Oct 2004 | A1 |
20040215126 | Ahmed | Oct 2004 | A1 |
20040216749 | Tu | Nov 2004 | A1 |
20040225250 | Yablonski | Nov 2004 | A1 |
20040254519 | Tu et al. | Dec 2004 | A1 |
20040254520 | Porteous et al. | Dec 2004 | A1 |
20040254521 | Simon | Dec 2004 | A1 |
20040260227 | Lisk, Jr. et al. | Dec 2004 | A1 |
20040260228 | Lynch et al. | Dec 2004 | A1 |
20050008673 | Snyder et al. | Jan 2005 | A1 |
20050038498 | Dubrow et al. | Feb 2005 | A1 |
20050049578 | Tu et al. | Mar 2005 | A1 |
20050055075 | Pinchuk et al. | Mar 2005 | A1 |
20050107734 | Coroneo | May 2005 | A1 |
20050119601 | Lynch et al. | Jun 2005 | A9 |
20050119737 | Bene et al. | Jun 2005 | A1 |
20050125003 | Pinchuk et al. | Jun 2005 | A1 |
20050137538 | Kunzler et al. | Jun 2005 | A1 |
20050159660 | Montegrande et al. | Jul 2005 | A1 |
20050171507 | Christian et al. | Aug 2005 | A1 |
20050175708 | Carrasquillo et al. | Aug 2005 | A1 |
20050182350 | Nigam | Aug 2005 | A1 |
20050184004 | Rodgers et al. | Aug 2005 | A1 |
20050186279 | Guo et al. | Aug 2005 | A1 |
20050192527 | Gharib et al. | Sep 2005 | A1 |
20050209549 | Bergheim et al. | Sep 2005 | A1 |
20050232972 | Odrich | Oct 2005 | A1 |
20050240143 | Dohlman | Oct 2005 | A1 |
20050244461 | Nivaggioli et al. | Nov 2005 | A1 |
20050244467 | Nivaggioli et al. | Nov 2005 | A1 |
20050244477 | Hughes et al. | Nov 2005 | A1 |
20050250788 | Tu et al. | Nov 2005 | A1 |
20050261624 | Wilcox | Nov 2005 | A1 |
20050267397 | Bhalla | Dec 2005 | A1 |
20050267398 | Protopsaltis et al. | Dec 2005 | A1 |
20050273033 | Grahn et al. | Dec 2005 | A1 |
20050276841 | Davis et al. | Dec 2005 | A1 |
20050277864 | Haffner et al. | Dec 2005 | A1 |
20050281861 | Hughes et al. | Dec 2005 | A1 |
20050288619 | Savage | Dec 2005 | A1 |
20060009498 | Whitcup | Jan 2006 | A1 |
20060020253 | Prescott | Jan 2006 | A1 |
20060032507 | Tu | Feb 2006 | A1 |
20060036207 | Koonmen et al. | Feb 2006 | A1 |
20060067978 | Heiler et al. | Mar 2006 | A1 |
20060069340 | Simon | Mar 2006 | A1 |
20060074375 | Bergheim et al. | Apr 2006 | A1 |
20060079828 | Brown | Apr 2006 | A1 |
20060083772 | DeWitt et al. | Apr 2006 | A1 |
20060084907 | Bergheim et al. | Apr 2006 | A1 |
20060116626 | Smedley et al. | Jun 2006 | A1 |
20060129129 | Smith | Jun 2006 | A1 |
20060155300 | Stamper et al. | Jul 2006 | A1 |
20060173397 | Tu et al. | Aug 2006 | A1 |
20060195055 | Bergheim et al. | Aug 2006 | A1 |
20060195056 | Bergheim et al. | Aug 2006 | A1 |
20060200113 | Haffner et al. | Sep 2006 | A1 |
20060210604 | Dadey et al. | Sep 2006 | A1 |
20060235367 | Takashima et al. | Oct 2006 | A1 |
20060241749 | Tu et al. | Oct 2006 | A1 |
20060246112 | Snyder et al. | Nov 2006 | A1 |
20060257450 | Mudumba et al. | Nov 2006 | A1 |
20060257451 | Varner et al. | Nov 2006 | A1 |
20060276738 | Becker | Dec 2006 | A1 |
20060276739 | Brown | Dec 2006 | A1 |
20060292222 | Jonasse | Dec 2006 | A1 |
20070004998 | Rodgers et al. | Jan 2007 | A1 |
20070031472 | Huang et al. | Feb 2007 | A1 |
20070032734 | Najafi et al. | Feb 2007 | A1 |
20070059336 | Hughes et al. | Mar 2007 | A1 |
20070073390 | Lee | Mar 2007 | A1 |
20070078371 | Brown et al. | Apr 2007 | A1 |
20070088014 | Edelman et al. | Apr 2007 | A1 |
20070088432 | Solovay et al. | Apr 2007 | A1 |
20070093740 | Shetty | Apr 2007 | A1 |
20070106199 | Krivoy et al. | May 2007 | A1 |
20070106200 | Levy | May 2007 | A1 |
20070112263 | Fink et al. | May 2007 | A1 |
20070118065 | Pinchuk et al. | May 2007 | A1 |
20070118066 | Pinchuk et al. | May 2007 | A1 |
20070123767 | Montegrande et al. | May 2007 | A1 |
20070123812 | Pinchuk et al. | May 2007 | A1 |
20070129623 | Fleischman et al. | Jun 2007 | A1 |
20070154621 | Raad | Jul 2007 | A1 |
20070156079 | Brown | Jul 2007 | A1 |
20070179426 | Selden | Aug 2007 | A1 |
20070185468 | Prywes | Aug 2007 | A1 |
20070191863 | De Juan, Jr. et al. | Aug 2007 | A1 |
20070207186 | Scanlon et al. | Sep 2007 | A1 |
20070212386 | Patravale et al. | Sep 2007 | A1 |
20070212387 | Patravale et al. | Sep 2007 | A1 |
20070212388 | Patravale et al. | Sep 2007 | A1 |
20070212393 | Patravale et al. | Sep 2007 | A1 |
20070212395 | Donello et al. | Sep 2007 | A1 |
20070219632 | Castillejos | Sep 2007 | A1 |
20070233037 | Gifford, III et al. | Oct 2007 | A1 |
20070260201 | Prausnitz et al. | Nov 2007 | A1 |
20070276315 | Haffner | Nov 2007 | A1 |
20070276316 | Haffner | Nov 2007 | A1 |
20070282244 | Tu et al. | Dec 2007 | A1 |
20070282245 | Tu et al. | Dec 2007 | A1 |
20070292470 | Thornton | Dec 2007 | A1 |
20070292474 | Hsu et al. | Dec 2007 | A1 |
20070293807 | Lynch et al. | Dec 2007 | A1 |
20070293872 | Peyman | Dec 2007 | A1 |
20070298068 | Badawi et al. | Dec 2007 | A1 |
20070298073 | Whitcup et al. | Dec 2007 | A1 |
20070298074 | Robinson et al. | Dec 2007 | A1 |
20080027304 | Pardo et al. | Jan 2008 | A1 |
20080038316 | Wong et al. | Feb 2008 | A1 |
20080039931 | Jelle et al. | Feb 2008 | A1 |
20080045878 | Bergheim et al. | Feb 2008 | A1 |
20080057101 | Roorda | Mar 2008 | A1 |
20080057102 | Roorda | Mar 2008 | A1 |
20080057103 | Roorda | Mar 2008 | A1 |
20080058704 | Hee et al. | Mar 2008 | A1 |
20080081064 | Jelle et al. | Apr 2008 | A1 |
20080082078 | Berlin | Apr 2008 | A1 |
20080107694 | Trogden et al. | May 2008 | A1 |
20080108932 | Rodgers | May 2008 | A1 |
20080108934 | Berlin | May 2008 | A1 |
20080112923 | Hughes et al. | May 2008 | A1 |
20080125691 | Yaron et al. | May 2008 | A1 |
20080131484 | Robinson et al. | Jun 2008 | A1 |
20080147021 | Jani | Jun 2008 | A1 |
20080147168 | Ransbury et al. | Jun 2008 | A1 |
20080152694 | Lobl et al. | Jun 2008 | A1 |
20080161741 | Bene et al. | Jul 2008 | A1 |
20080161907 | Chen et al. | Jul 2008 | A1 |
20080177153 | Bachman et al. | Jul 2008 | A1 |
20080200860 | Tu et al. | Aug 2008 | A1 |
20080210322 | Unger et al. | Sep 2008 | A1 |
20080221501 | Cote et al. | Sep 2008 | A1 |
20080228127 | Burns et al. | Sep 2008 | A1 |
20080236669 | Unger et al. | Oct 2008 | A1 |
20080243243 | Williams et al. | Oct 2008 | A1 |
20080243247 | Poley et al. | Oct 2008 | A1 |
20080277007 | Unger et al. | Nov 2008 | A1 |
20080289710 | Unger et al. | Nov 2008 | A1 |
20080292679 | Lyons et al. | Nov 2008 | A1 |
20080306429 | Shields et al. | Dec 2008 | A1 |
20090036768 | Seehusen et al. | Feb 2009 | A1 |
20090036818 | Grahn et al. | Feb 2009 | A1 |
20090043321 | Conston et al. | Feb 2009 | A1 |
20090069648 | Irazoqui et al. | Mar 2009 | A1 |
20090076436 | Gharib et al. | Mar 2009 | A2 |
20090082321 | Edelman et al. | Mar 2009 | A1 |
20090082860 | Schieber et al. | Mar 2009 | A1 |
20090082862 | Schieber et al. | Mar 2009 | A1 |
20090082863 | Schieber et al. | Mar 2009 | A1 |
20090104248 | Rapacki et al. | Apr 2009 | A1 |
20090118702 | Lazar | May 2009 | A1 |
20090123515 | Taylor et al. | May 2009 | A1 |
20090132040 | Frion et al. | May 2009 | A1 |
20090137992 | Mallakrishnan | May 2009 | A1 |
20090138081 | Bergheim et al. | May 2009 | A1 |
20090148498 | Libin et al. | Jun 2009 | A1 |
20090149947 | Frohwitter | Jun 2009 | A1 |
20090151422 | Unger et al. | Jun 2009 | A1 |
20090155338 | Conway et al. | Jun 2009 | A1 |
20090177138 | Brown et al. | Jul 2009 | A1 |
20090204053 | Nissan et al. | Aug 2009 | A1 |
20090214619 | Reiff et al. | Aug 2009 | A1 |
20090220572 | Deschatelets et al. | Sep 2009 | A1 |
20090227933 | Karageozian | Sep 2009 | A1 |
20090227934 | Eutenever et al. | Sep 2009 | A1 |
20090264861 | Jain et al. | Oct 2009 | A1 |
20090275924 | Lattanzio et al. | Nov 2009 | A1 |
20090280158 | Butuner | Nov 2009 | A1 |
20090287136 | Castillejos | Nov 2009 | A1 |
20090326432 | Schmidt et al. | Dec 2009 | A1 |
20100004635 | Lin et al. | Jan 2010 | A1 |
20100015195 | Jain et al. | Jan 2010 | A1 |
20100025613 | Tai et al. | Feb 2010 | A1 |
20100042209 | Guarnieri | Feb 2010 | A1 |
20100056977 | Wandel | Mar 2010 | A1 |
20100056979 | Smedley et al. | Mar 2010 | A1 |
20100057055 | Camras et al. | Mar 2010 | A1 |
20100087774 | Haffner et al. | Apr 2010 | A1 |
20100106073 | Haffner et al. | Apr 2010 | A1 |
20100114006 | Baerveldt | May 2010 | A1 |
20100121342 | Schieber et al. | May 2010 | A1 |
20100125237 | Schocket | May 2010 | A1 |
20100145180 | Abreu | Jun 2010 | A1 |
20100158980 | Kopczynski et al. | Jun 2010 | A1 |
20100168644 | Brown | Jul 2010 | A1 |
20100175767 | Unger et al. | Jul 2010 | A1 |
20100185138 | Yaron et al. | Jul 2010 | A1 |
20100191103 | Stamper et al. | Jul 2010 | A1 |
20100191329 | Badawi et al. | Jul 2010 | A1 |
20100222733 | Schieber et al. | Sep 2010 | A1 |
20100225061 | Bath | Sep 2010 | A1 |
20100234791 | Lynch et al. | Sep 2010 | A1 |
20100241046 | Pinchuk et al. | Sep 2010 | A1 |
20100249691 | Van der Mooren et al. | Sep 2010 | A1 |
20100255061 | de Juan, Jr. et al. | Oct 2010 | A1 |
20100274259 | Yaron et al. | Oct 2010 | A1 |
20100278898 | Hughes et al. | Nov 2010 | A1 |
20110009874 | Wardle et al. | Jan 2011 | A1 |
20110009958 | Wardle et al. | Jan 2011 | A1 |
20110046536 | Stegmann et al. | Feb 2011 | A1 |
20110046728 | Shareef et al. | Feb 2011 | A1 |
20110054418 | Pugh et al. | Mar 2011 | A1 |
20110066098 | Stergiopulos | Mar 2011 | A1 |
20110071454 | Dos Santos et al. | Mar 2011 | A1 |
20110071456 | Rickard | Mar 2011 | A1 |
20110071458 | Rickard | Mar 2011 | A1 |
20110071459 | Rickard et al. | Mar 2011 | A1 |
20110071505 | Rickard et al. | Mar 2011 | A1 |
20110086095 | Jacob et al. | Apr 2011 | A1 |
20110092878 | Tu et al. | Apr 2011 | A1 |
20110098627 | Wilcox | Apr 2011 | A1 |
20110098640 | Horne et al. | Apr 2011 | A1 |
20110098809 | Wardle et al. | Apr 2011 | A1 |
20110105987 | Bergheim et al. | May 2011 | A1 |
20110106006 | Martin et al. | May 2011 | A1 |
20110112475 | Benson | May 2011 | A1 |
20110118649 | Stegmann et al. | May 2011 | A1 |
20110118835 | Silvestrini et al. | May 2011 | A1 |
20110130831 | Badawi et al. | Jun 2011 | A1 |
20110144559 | Lafdi et al. | Jun 2011 | A1 |
20110196487 | Badawi et al. | Aug 2011 | A1 |
20110224597 | Stegmann et al. | Sep 2011 | A1 |
20110244014 | Williams et al. | Oct 2011 | A1 |
20110245753 | Williams et al. | Oct 2011 | A1 |
20110248671 | Dos Santos et al. | Oct 2011 | A1 |
20110251568 | Beeley et al. | Oct 2011 | A1 |
20110257623 | Marshall et al. | Oct 2011 | A1 |
20110319806 | Wardle | Dec 2011 | A1 |
20120010702 | Stegmann et al. | Jan 2012 | A1 |
20120022424 | Yamamoto et al. | Jan 2012 | A1 |
20120035524 | Silvestrini | Feb 2012 | A1 |
20120035528 | Coppeta et al. | Feb 2012 | A1 |
20120059338 | Beeley et al. | Mar 2012 | A1 |
20120059461 | Badawi et al. | Mar 2012 | A1 |
20120071809 | Tu et al. | Mar 2012 | A1 |
20120078158 | Haffner et al. | Mar 2012 | A1 |
20120078362 | Haffner et al. | Mar 2012 | A1 |
20120089072 | Cunningham, Jr. | Apr 2012 | A1 |
20120089073 | Cunningham, Jr. | Apr 2012 | A1 |
20120109040 | Smedley et al. | May 2012 | A1 |
20120130467 | Selden et al. | May 2012 | A1 |
20120165933 | Haffner et al. | Jun 2012 | A1 |
20120179087 | Schieber et al. | Jul 2012 | A1 |
20120184892 | Bigler et al. | Jul 2012 | A1 |
20120197217 | Coldren | Aug 2012 | A1 |
20120203160 | Kahook et al. | Aug 2012 | A1 |
20120238994 | Nazzaro et al. | Sep 2012 | A1 |
20120257167 | Gille et al. | Oct 2012 | A1 |
20120259195 | Haffner et al. | Oct 2012 | A1 |
20120289883 | Meng et al. | Nov 2012 | A1 |
20120302861 | Marshall et al. | Nov 2012 | A1 |
20120310072 | Grieshaber | Dec 2012 | A1 |
20120323159 | McDonnell et al. | Dec 2012 | A1 |
20130006164 | Yaron et al. | Jan 2013 | A1 |
20130006165 | Eutenener et al. | Jan 2013 | A1 |
20130018295 | Haffner et al. | Jan 2013 | A1 |
20130018296 | Bergheim et al. | Jan 2013 | A1 |
20130079701 | Schieber et al. | Mar 2013 | A1 |
20130090534 | Burns et al. | Apr 2013 | A1 |
20130102949 | Baerveldt | Apr 2013 | A1 |
20130144202 | Field et al. | Jun 2013 | A1 |
20130150770 | Horvath et al. | Jun 2013 | A1 |
20130150773 | Nissan et al. | Jun 2013 | A1 |
20130150774 | Field et al. | Jun 2013 | A1 |
20130150776 | Bohm et al. | Jun 2013 | A1 |
20130150777 | Bohm et al. | Jun 2013 | A1 |
20130150779 | Field | Jun 2013 | A1 |
20130150959 | Schieber et al. | Jun 2013 | A1 |
20130158381 | Rickard | Jun 2013 | A1 |
20130158462 | Wardle et al. | Jun 2013 | A1 |
20130165840 | Orge | Jun 2013 | A1 |
20130172804 | Schieber et al. | Jul 2013 | A1 |
20130184631 | Pinchuk | Jul 2013 | A1 |
20130245532 | Tu et al. | Sep 2013 | A1 |
20130253404 | Tu | Sep 2013 | A1 |
20130253405 | Tu | Sep 2013 | A1 |
20130253528 | Haffner et al. | Sep 2013 | A1 |
20130281910 | Tu et al. | Oct 2013 | A1 |
20130310930 | Tu et al. | Nov 2013 | A1 |
20140034607 | Meng et al. | Feb 2014 | A1 |
20140046437 | Renke | Feb 2014 | A1 |
20140052046 | Peartree et al. | Feb 2014 | A1 |
20140135916 | Clauson et al. | May 2014 | A1 |
20140276332 | Crimaldi et al. | Sep 2014 | A1 |
20150148730 | Lynch et al. | May 2015 | A1 |
20150223981 | Smedley et al. | Aug 2015 | A1 |
20150342875 | Haffner | Dec 2015 | A1 |
20150374546 | Hill | Dec 2015 | A1 |
20160354309 | Heitzmann et al. | Dec 2016 | A1 |
20170135857 | Haffner et al. | May 2017 | A1 |
20170156848 | Schieber | Jun 2017 | A1 |
20170273829 | Tu et al. | Sep 2017 | A1 |
20180021170 | Haffner et al. | Jan 2018 | A1 |
20180028361 | Haffner et al. | Feb 2018 | A1 |
20180036172 | Haffner et al. | Feb 2018 | A1 |
20180085065 | Haffner et al. | Mar 2018 | A1 |
20180104102 | Lynch et al. | Apr 2018 | A1 |
20180161205 | Tu et al. | Jun 2018 | A1 |
20180280194 | Heitzmann et al. | Oct 2018 | A1 |
20180303665 | Heitzmann et al. | Oct 2018 | A1 |
20180325732 | Burns et al. | Nov 2018 | A1 |
20180333296 | Heitzmann et al. | Nov 2018 | A1 |
20180369017 | Schieber et al. | Dec 2018 | A1 |
20190000673 | Fjield et al. | Jan 2019 | A1 |
20190021991 | Heitzmann et al. | Jan 2019 | A9 |
20190053704 | Burns et al. | Feb 2019 | A1 |
20190083307 | Burns et al. | Mar 2019 | A1 |
20190083313 | Berlin | Mar 2019 | A1 |
20190104936 | Gunn et al. | Apr 2019 | A1 |
20190105077 | Kalina, Jr. et al. | Apr 2019 | A1 |
20190125581 | Heitzmann et al. | May 2019 | A1 |
20190224046 | Heitzmann et al. | Jul 2019 | A1 |
20190314199 | Haffner et al. | Oct 2019 | A1 |
20190321220 | Rangel-Friedman et al. | Oct 2019 | A1 |
20190321225 | Smedley et al. | Oct 2019 | A1 |
20200155349 | Haffner et al. | May 2020 | A1 |
20200367745 | Kalina, Jr. et al. | Nov 2020 | A1 |
20210015662 | Haffner et al. | Jan 2021 | A1 |
20210137737 | Burns et al. | May 2021 | A1 |
20210154449 | Haffner et al. | May 2021 | A1 |
20210298948 | Haffner et al. | Sep 2021 | A1 |
20210315806 | Haffner | Oct 2021 | A1 |
20210369447 | Kalina, Jr. | Dec 2021 | A1 |
20220000663 | Haffner et al. | Jan 2022 | A1 |
20220015628 | Kalina, Jr. et al. | Jan 2022 | A1 |
20220233349 | Haffner et al. | Jul 2022 | A1 |
20220233354 | Haffner et al. | Jul 2022 | A1 |
Number | Date | Country |
---|---|---|
199876197 | Feb 1999 | AU |
200072059 | Jul 2001 | AU |
2004264913 | Dec 2011 | AU |
2009251058 | Dec 2013 | AU |
2273331 | Jun 1998 | CA |
2244646 | Feb 1999 | CA |
2311244 | Jun 1999 | CA |
2442652 | Jan 2011 | CA |
2766131 | Jan 2011 | CA |
2683224 | Dec 2014 | CA |
2830555 | Apr 2015 | CA |
2762536 | Nov 2020 | CA |
92111244 | Jul 1993 | CH |
101396335 | Apr 2009 | CN |
19840047 | Mar 2000 | DE |
10127666 | Jan 2003 | DE |
0550791 | Jul 1993 | EP |
0858788 | Aug 1998 | EP |
0898947 | Mar 1999 | EP |
1114627 | Jul 2001 | EP |
1592407 | Nov 2005 | EP |
1977724 | Oct 2008 | EP |
2260803 | Dec 2010 | EP |
2260804 | Dec 2010 | EP |
2263621 | Dec 2010 | EP |
2351589 | Aug 2011 | EP |
2982354 | Feb 2016 | EP |
2985012 | Feb 2016 | EP |
2553658 | Apr 1985 | FR |
2710269 | Mar 1995 | FR |
9311476 | Mar 1995 | FR |
2721499 | Dec 1995 | FR |
2757068 | Jun 1998 | FR |
2296663 | Jul 1996 | GB |
2005-502811 | May 1993 | JP |
2010-248869 | Sep 1998 | JP |
2011-123205 | May 1999 | JP |
2001-523519 | Nov 2001 | JP |
2002-541977 | Dec 2002 | JP |
2001-507969 | Jan 2003 | JP |
2004-518450 | Jun 2004 | JP |
3703721 | Jul 2005 | JP |
2005-525835 | Sep 2005 | JP |
2007-535386 | Dec 2007 | JP |
2008-500878 | Jan 2008 | JP |
4031836 | Jan 2008 | JP |
2009-523540 | Jun 2009 | JP |
2009-542370 | Dec 2009 | JP |
2010-533565 | Oct 2010 | JP |
4688444 | Feb 2011 | JP |
2011-520805 | Jul 2011 | JP |
2011-522575 | Aug 2011 | JP |
2012-516224 | Jul 2012 | JP |
2012-198134 | Sep 2012 | JP |
2013-063308 | Apr 2013 | JP |
5255402 | Apr 2013 | JP |
5323011 | Jul 2013 | JP |
2013-208434 | Oct 2013 | JP |
5502811 | May 2014 | JP |
2014-193366 | Oct 2014 | JP |
2014-240022 | Dec 2014 | JP |
2022539 | Nov 1994 | RU |
2143250 | Dec 1999 | RU |
WO 8900869 | Feb 1989 | WO |
WO 9108784 | Jun 1991 | WO |
WO 9118568 | Dec 1991 | WO |
WO 9200112 | Jan 1992 | WO |
WO 9219294 | Nov 1992 | WO |
WO 9413234 | Jun 1994 | WO |
WO 9508310 | Mar 1995 | WO |
WO 1996020742 | Jul 1996 | WO |
WO 9636377 | Nov 1996 | WO |
WO 9823237 | Jun 1998 | WO |
WO 9830181 | Jul 1998 | WO |
WO 9835639 | Aug 1998 | WO |
WO 9837831 | Sep 1998 | WO |
WO 9926567 | Jun 1999 | WO |
WO 9930641 | Jun 1999 | WO |
WO 9938470 | Aug 1999 | WO |
WO 199956637 | Nov 1999 | WO |
WO 0013627 | Mar 2000 | WO |
WO 0064390 | Nov 2000 | WO |
WO 0064391 | Nov 2000 | WO |
WO 0064393 | Nov 2000 | WO |
WO 0067687 | Nov 2000 | WO |
WO 200064389 | Nov 2000 | WO |
WO 0072788 | Dec 2000 | WO |
WO 0141685 | Jun 2001 | WO |
WO 0150943 | Jul 2001 | WO |
WO 0178631 | Oct 2001 | WO |
WO 0178656 | Oct 2001 | WO |
WO 2001080825 | Nov 2001 | WO |
WO 0197727 | Dec 2001 | WO |
WO 0236052 | May 2002 | WO |
WO 2002053129 | Jul 2002 | WO |
WO 02074052 | Sep 2002 | WO |
WO 02080811 | Oct 2002 | WO |
WO 02102274 | Dec 2002 | WO |
WO 03015659 | Feb 2003 | WO |
WO 03041622 | May 2003 | WO |
WO 03045290 | Jun 2003 | WO |
WO 2003061625 | Jul 2003 | WO |
WO 03073968 | Sep 2003 | WO |
WO 2004043435 | May 2004 | WO |
WO 2004073552 | Sep 2004 | WO |
WO 2004093761 | Nov 2004 | WO |
WO 05046782 | May 2005 | WO |
WO 05055873 | Jun 2005 | WO |
WO 05107664 | Nov 2005 | WO |
WO 2007087061 | Aug 2007 | WO |
WO 2008005873 | Jan 2008 | WO |
WO 08061043 | May 2008 | WO |
WO 2008060359 | May 2008 | WO |
WO 2008083118 | Jul 2008 | WO |
WO 2008157614 | Dec 2008 | WO |
WO 2009012406 | Jan 2009 | WO |
WO 2009035571 | Mar 2009 | WO |
WO 2009063222 | May 2009 | WO |
WO 2009126569 | Oct 2009 | WO |
WO 2009151543 | Dec 2009 | WO |
WO 2010006053 | Jan 2010 | WO |
WO 2010078063 | Jul 2010 | WO |
WO 10135369 | Nov 2010 | WO |
WO 11020633 | Feb 2011 | WO |
WO 2011127064 | Oct 2011 | WO |
WO 12071476 | May 2012 | WO |
WO 13148275 | Oct 2013 | WO |
WO 2017030917 | Feb 2017 | WO |
WO 2019036025 | Feb 2019 | WO |
Entry |
---|
Johnson et al., “Schlemm's Canal Becomes Smaller After Successful Filtration Surgery”, (reprinted) ARCM Ophthalmol/vol. 118, Sep. 2000 (www.archophthalmol.com) p. 1251-1256. |
International Preliminary Report on Patentability in PCT/US2016/053570 dated Mar. 27, 2018. |
Alexander, L., et al., Disistronic Polioviruses as Expression Vectors for Foreign Genes. 1994. Aids Research and Human Retroviruses. vol. 10, Supplement 2, S57-S60. |
Bae, et al., “In vitro experiment of the pressure regulating valve for a glaucoma implant”, Journal of Micromechanics and Microengineering 13.5, 13:613-619, No. 5, Sep. 2003. |
Bucciarelli, Patrice D., Working Model is Next Step in Team's Long Journey to Commercial Product, Healthfirst, Business First of Louisville, louisville.bizjournals.com, Feb. 27, 2004. |
“Changing Perspectives in Glaucoma Management,” Innovations in Glaucoma 2010. |
Cairns, J.E., “Trabeculectomy: Preliminary report of a new method”, Am. J. Ophthalmology, 66:673-79 (1968). |
Chen, et al., “Trabeculetomy combined with implantation of silicon rubber slice for intractable glaucoma”, Eye Science, 18:95-98, vol. 2, Jun. 2002. |
Fine, Ben S., et al., “A Clinicopathologic Study of Four Cases of Primary Open-Angle Glaucoma Compared to Normal Eyes”, American Journal of Ophthalmology, vol. 91, No. 1, 1981, pp. 88-105. |
Fiore, P.M., et al., Use of neodymium: YAG laser to open an occluded molteno tube, Ophthalmic Surgery, May 1989; 20(5): 373-74. |
Gimbel, H.V., et al., “Small incision trabeculotomy combined with phacoemulsificatin and intraocular lens implantation”, J Cataract Refract Surg, vol. 19:92-96 (Jan. 1993). |
Gothwal, et al., “Migration of seton into the anterior chamber”, Eye, 16:85-97, 2002. |
Hoskins, H. Dunbar, et al., Diagnosis and Therapy of the Glaucomas, Chapter 4: Aqueous Humor Outflow, 61 edition, pp. 41-66 (1989) (28 pages). |
Huang, Morgan C., et al., Intermediate-term Clinical Experience with the Ahmed Glaucoma Valve Implant, 127 Am. J. Ophthalmol. 27 (Jan. 1999). |
Jordon, et al., “A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma,” J Glaucoma 15(3): 200-205 (2006). |
Kampik, Anselm Franz Grehn, Nutzen und Risiken Augenärzticher Therapie, Hauotreferate der XXXIII, Essener Fortbildung für Augenärzte, Dec. 1998. (English translated version enclosed Benefits and Risks of Opthalmological Therapy). |
Kershner, Robert, “Nonpenetrating trabulectomy with placement of a collagen drainage device”, J. Cataract Refract. Sug., 21:608-611 (1995). |
Klemm, A. Balazs, J. Draeger, R. Wiezorrek, Experimental use of space-retaining substances with extended duration: functional and morphological results, Graefe's Arch Clin Exp Ophthalmol (1995) 233:592-597. |
Krupin, Theodore, et al., Filtering valve implant surgery for eyes with neovascular glaucoma, 89 Am. J. Ophthalmol. 338 (Mar. 1980). |
Mermoud, A., et al., “Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma”, J. Cataracat Refract. Surg., vol. 25, No. 3, Mar. 1999, pp. 323-331 (abstract only). |
Miyazaki, Akiko, et al., Postoperative Results Of Combined Trabeculotomy, Phacoemulsification And Intraocular Lens Implantation With Self-Sealing Wound, Japanese Journal of Ophthalmic Surgery, 1997, pp. 537-542, vol. 10, No. 4. |
Molteno, A.C.B., et al., Implants for draining neovascular glaucoma, 61 Br. J. Ophthalmol. 120 (1977). |
Moses, Robert A., M.D.; Circumferential Flow in Schlemm's Canal; American Journal of Ophthalmology, Sep. 1979, vol. 88, No. 3, Part II, :pp. 585-591. |
Nguyen, Quang H., et al., Complications of Baerveldt Glaucoma Drainage Implants, 116 Arch. Ophthalmol. 571 (May 1998). |
Refojo, “Current status of biomaterials in ophthalmology”, Survey of ophthalmology, 26:257-265, No. 5, 1982. |
Rizq, et al., Intraocular Pressure Measurement at the Choroid Surface: A Feasibility Study with Implications for Implantable Microsystems, Br J Ophthalmol 2001; 85:868-871, Jul. 2001. |
Saxena, Sandeep. “Clinical Ophthalmology”. 2011. pp. 245. |
Schocket, Investigations of the Reasons for Success and Failure in the Anterior Shunt-to-the Encircling-Band Procedure in the Treatment of Refractory Glaucoma, Tr. Am. Ophth. Soc., 84:743 (1986). |
Scott, et al., “Use of glaucoma drainage devices in the management of glaucoma associated with aniridia”, American Journal of Ophthalmology, 135:155-159, No. 2, Feb. 1, 2003. |
Shields, M. Bruce, MD, A Study Guide for Glaucoma: Aqueous Humor Dynamics, Copyright 1982, pp. 6-43. |
Stefansson, J., “An Operation for Glaucoma”, American J. Ophthalmology, 8:681-693 (1925). |
“Transcend Medical CyPass® System—Instructions for Use,” (Release date Apr. 29, 2013). |
Tham, et al., “Incisional surgery for angle closure glaucoma”, Seminars in Ophthalmology, 17:92-99, No. 2, Jun. 2002. |
Topouzis, Fotis, et al., Follow-up of the Original Cohort With the Ahmed Glaucoma Valve Implant, 128 Am. J. Ophthalmol. 198 (Aug. 1999). |
Tripathi, et al., Functional Anatomy of the Anterior Chamber Angle, Biomedical Foundation of Ophthalmology, vol. 1, Chapter 10,pp. 1-74; edited by Thomas Dune and Edward Jaeger, Revised Edition, 1983,—Harper & Row, Publishers. |
Tun, et al., Assessment of Trabecular Meshwork Width Using Swept Source Optical Coherence Tomography, 251:6 Graefes Arch. Clin. Exp. Ophthalmol. 1587 (2013). |
Wagner, Justin A., Edwards, Aurélie, and Schuman, Joel S., Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused Under Constant Pressure, Invest Ophthalmol Vis Sci. Sep. 2004; 45(9): 3203-3206 (9 pages). |
Webster's Third New International Dictionary of the English Language (Unabridged), definitions of “deploy” and “deployment”, p. 605 (2002) (4 pages). |
Wilcox, Michael J. et al. “Hypothesis for Improving Accessory Filtration by Using Geometry”, J. Glaucoma, vol. 3, No. 3, pp. 244-247 (1994). |
Wilcox, Michael J. et al. “Performance of a New, Low-volume, High-Surface Area Aqueous Shunt in Normal Rabbit Eyes”, J. Glaucoma, vol. 9, No. 1, pp. 74-82 (Feb. 2000). |
Wilson, Ellen D., “Implants offer choices for glaucoma surgeons”, EW Glaucoma, Oct. 11, 1999, website “http://www.eyeorld.org/sep99/999p60.asp”. |
Wilcox et al., Latest Research: Tear Biomarkers, Jun. 29, 2011, 5 pages. |
Yan, et al., “Schlemm's Canal and Trabecular Meshwork in Eyes with Primary Open Angle Glaucoma: A Comparative Study Using High-Frequency”, PLOS One, 15 pages, Jan. 4, 2016. |
European Exam Report, EPO App. No. 08 102 896.1, dated Nov. 4, 2010. |
Communication from European Patent Office for European App. No. 08102896.1 (dated Jul. 2, 2012). |
Appeal in European Application No. 08102896.1 dated Aug. 27, 2012. |
International Search Report and Written Opinion in PCT/US2016/053570 dated Mar. 9, 2017. |
International Preliminary Report on Patentability in PCT/US2016/053570 dated Jan. 23, 2018. |
Chen et al., “Implantable Unpowered Parylene MEMS Intraocular Pressure Sensor”, Microtechnologies in Medicine and Biology, 2006 International Conference on Publication Date: May 9-12, 2006, 5pp., downloaded from http://ieeezxplore.ieee.org/xpl/freeabs_all.jsp?arnumber=4281361. |
Grant, W.M., MD, “Further Studies on Facility of Flow Through the Trabecular Meshwork”, AMA Archives of Ophthalmology, Oct. 1958, vol. 60, pp. 523-533. |
https://entokey.com/gonioscopy-2/ Uploaded Oct. 2016. |
Hulzen et al., “Effect of Fixation on Juxtacanalicular Tissue and Schlemm's canal”, Investigative Ophthalmology & Visual Science, vol. 37, No. 1 (Jan. 1996). |
Jain et al., “Development of polyvinyl alcohol-gelatin membranes for antibiotic delivery in the eye”, Drug Development and Industrial Pharmacy, 2011, Informa Healthcare USA, Inc., 12 pages. |
Johnson, et al. “Mechanisms and Routes of Aqueous Humor Drainage” in D.M. Albert, & F.A. Jakobiec (Eds.), Principles and Practice of Ophthalmology, pp. 2577-2595, WB Saunders, Philadelphia (2000). |
Katuri et al., “Intraocular Pressure Monitoring Sensors”, IEEE Sensors Journal, vol. 8, No. 1, Jan. 2008, 8 pp. |
McLaren et al., “Continuous Measurement of Intraocular Pressure in Rabbits by Telemetry,” Investigative Ophthalmology & Visual Science, vol. 37, No. 6, pp. 966-975, May 1996. |
Online encyclopedia article “Hyaluronan,” section on “Medical Applications” accessed Monday, Sep. 27, 2010. http://en.wikipedia.org/wiki/Hyaluronic_acid. |
Sampaolesi, et al., “Scanning Electron Microscopy of the Trabecular Meshwork in Normal-Glaucomatous Eyes”, Invest Ophthalmol Vis Sci, pp. 302-314 (1977). |
Spiegel, Detlev, “Benefits and Risks of Ophthalmological Treatment” Bucherei des Augenarztes I The Ophthalmologist's Library, vol. 139, Oct. 15, 1998. |
Spiegel, “7 chirurgische Glaukomtherapie”, pp. 79-88 (English translation enclosed). |
Spiegel et al., “Schlemm's Canal Implant: A New Method to Lower Intraocular Pressure in Patients With POAG”, Opthalmic Surgery and Lasers, vol. 30(6):492-494 (1999). |
Ianchulev et al., “Minimally Invasive Ab-Interno Suprachoroidal Device (CyPass) for IOP Control in Open-Angle Glaucoma,” presented at the Annual Meeting of the American Academy of Ophthalmology Oct. 16-19, 2010, Chicago, IL. |
Walter et al., “Development of a Completely Encapsulated Intraocular Pressure Sensor”, Ophthalmic Res 2000; 32:278-284. Nov. 1999. |
Number | Date | Country | |
---|---|---|---|
20200179171 A1 | Jun 2020 | US |
Number | Date | Country | |
---|---|---|---|
61794832 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14207240 | Mar 2014 | US |
Child | 16717957 | US |